Is Syncom Formulations stock a buy?
What Is The Conclusion?
Right now our advanced algorithms say:
Do the analyst corps agree?
Interesting Questions and Easy Answers!
Yes, Syncom Formulations pays dividends. Last time was Wednesday 19th of October 2022 where the investors holding the stock on Friday 9th of September 2022 were paid INR0.03 per share. Over the last 2 times between 2017 and 2022, Syncom Formulations has paid INR0.05 with an average of INR0.03 per share.
Sorry, we do not have any analyst data for this ticker
We cannot find data for Syncom Formulations 10 years ago, but if you had invested on Friday 18th of November 2022 when the price was INR8.10, you would have made a profit of INR15.03 per share or 185.56%
Yes, the average daily trading liquidity for Syncom Formulations is INR10.22 million. You should therefore be able to get in and out of your positions relatively fast.
Syncom Formulations has a normal ratio of the business financed by loans. This puts the company at some risk in periods of high inflation where borrowing costs usually go up. With a low cash flow to debt ratio of 0.09, the company's ability to pay off the debt is limited. Syncom Formulations has a good net profit margin of 9.61% and should have high tolerances against inflation.
We have calculated the inflation risk for Syncom Formulations to be medium [0.55 of 1]
US inflation for July 2024 was 0.15%. Over the last 12 months, the US inflation is 2.92%. The 10-year treasury yield that indicates the future interest level is currently 3.72 and is down -0.95 over the last 30 days.